Evidence map›Paper›PMID 27113164›Full record

ArticleVaccine2016

Antigen nature and complexity influence human antibody light chain usage and specificity.

Kenneth Smith, Hemangi Shah, Jennifer J Muther, Angie L Duke, Kathleen Haley, Judith A James

Abstract read
In one paragraph

Article in Vaccine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Kenneth SmithOklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK 73104, USA. Electronic address: Kenneth-Smith@omrf.org.
Hemangi ShahOklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK 73104, USA; Pamlico BioPharma Inc., 865 Research Parkway, Suite 400, Oklahoma City, OK 73104, USA.
Jennifer J MutherOklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK 73104, USA.
Angie L DukeOklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK 73104, USA.
Kathleen HaleyOklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK 73104, USA.
Judith A JamesOklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK 73104, USA; Oklahoma University Health Science Center, 1100 N. Lindsay, Oklahoma City, OK 73104, USA.
Oklahoma Medical Research Foundation · USOU Health

Funding

Tracking and Evaluation CoreU54GM104938 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Robert Hal Scofield · 2013 to 2026
$68.2M
Translation of immunologic technologies from basic research into pre-clinical nonU19AI062629 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI COGGESHALL, KENNETH MARK · 2004 to 2023
$56.2M
SNP Confirmation and High Throughput Genotyping CoreP30AR053483 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI GUTHRIDGE, JOEL MARVIN · 2007 to 2017
$6.7M
Pre-Clinical Studies to Identify SLE Therapeutic TargetsU19AI082714 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JAMES, JUDITH A · 2009 to 2018
$6.2M
Science in a Culture of MentoringP30GM103510 · NIGMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JAMES, JUDITH A · 2012 to 2016
$3.9M
Understanding early events in lupus autoimmunity to aid preventionU01AI101934 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JAMES, JUDITH A · 2012 to 2016
$2.3M
IMMUNE FUNCTION AND BIODEFENSE IN CHILDREN ELDERLY AND IMMUNOCOMPROMIS-266050026N01AI050026 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI THOMPSON, LINDA · 2006 to 2006
–
NIAID NIH HHS HHSN266200500026CNIAID NIH HHS N01 AI050026NIAID NIH HHS U01 AI101934NIAID NIH HHS U19 AI062629NIAID NIH HHS U19 AI082714NIAMS NIH HHS P30 AR053483NIGMS NIH HHS P30 GM103510NIGMS NIH HHS U54 GM104938
6 · The paper itself

Abstract

Human antibodies consist of a heavy chain and one of two possible light chains, kappa (κ) or lambda (λ). Here we tested how these two possible light chains influence the overall antibody response to polysaccharide and protein antigens by measuring light chain usage in human monoclonal antibodies from antibody secreting cells obtained following vaccination with Pneumovax23. Remarkably, we found that individuals displayed restricted light chain usage to certain serotypes and that lambda antibodies have different specificities and modes of cross-reactivity than kappa antibodies. Thus, at both the monoclonal (7 kappa, no lambda) and serum levels (145μg/mL kappa, 2.82μg/mL lambda), antibodies to cell wall polysaccharide were nearly always kappa. The pneumococcal reference serum 007sp was analyzed for light chain usage to 12 pneumococcal serotypes for which it is well characterized. Similar to results at the monoclonal level, certain serotypes tended to favor one of the light chains (14 and 19A, lambda; 6A and 23F, kappa). We also explored differences in light chain usage at the serum level to a variety of antigens. We examined serum antibodies to diphtheria toxin mutant CRM197 and Epstein-Barr virus protein EBNA-1. These responses tended to be kappa dominant (average kappa-to-lambda ratios of 4.52 and 9.72 respectively). Responses to the influenza vaccine were more balanced with kappa-to-lambda ratio averages having slight strain variations: seasonal H1N1, 1.1; H3N2, 0.96; B, 0.91. We conclude that antigens with limited epitopes tend to produce antibodies with restricted light chain usage and that in most individuals, antibodies with lambda light chains have specificities different and complementary to kappa-containing antibodies.

Indexed as

Antibody SpecificityAntibodies, BacterialAntibodies, MonoclonalAntibodies, ViralBacterial ProteinsCross ReactionsEpstein-Barr Virus Nuclear AntigensHerpesvirus 4, HumanHumansImmunoglobulin kappa-ChainsImmunoglobulin lambda-ChainsInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeInfluenza VaccinesPneumococcal Vaccines23-valent pneumococcal capsular polysaccharide vaccineAntibodies, BacterialAntibodies, MonoclonalAntibodies, ViralBacterial ProteinsCRM197 (non-toxic variant of diphtheria toxin)EBV-encoded nuclear antigen 1Epstein-Barr Virus Nuclear AntigensImmunoglobulin kappa-ChainsImmunoglobulin lambda-ChainsInfluenza VaccinesPneumococcal VaccinesAnti-polysaccharideHuman monoclonal antibodiesKappa light chainLambda light chainLight chain usage

Identifiers

PMID27113164
PMCPMC4876604
OpenAlexW2340329277

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.